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1. Introduction 
The post-millennium era witnesses a substantial epidemiologic transition in which 
cardiovascular disease (CVD) has taken more important role in mortality and morbidity in 
almost all parts of the world[1]. However, the natural history of CVD itself has also been 
evolving in parallel to changing life style and environmental risk factors. Nevertheless, despite 
a global movement for CVD control, the target points are still poorly achieved[2]. Therefore, a 
new look at the issue of CVD pathophysiology, CVD markers and risk assessment is necessary 
for a proper and effective care plan and targeting CVD prevention and control. 
The classification of some elements to "risk factors" and "risk markers" has been controversial. 
There have been serious debates about the validity and impact of classic CVD risk factors. 
However, it is generally accepted that classic CVD risk factors cannot fully explain the 
epidemiology and natural history of the disease particularly in patients with co-morbidities. 
As a result several lists of emerging risk factors have been introduced with various clinical 
or research applications. Accordingly, several risk scores have been developed for risk 
assessment among various populations. Nevertheless, we face a network of associated risk 
factors with synergic effects, of which some factors play central roles and connect other 
factors together. For instance, central arterial pressure and arterial stiffness and also 
microalbuminuria have attracted more attention as summative CVD markers or risk factors 
and have been proposed as new targets for more efficient treatment.  
Increasing evidence of cross-links among CVD, diabetes mellitus (DM) and chronic kidney 
disease (CKD) has been published in recent decades. DM and CKD are major comorbidities 
with CVD. In addition, several studies demonstrated greater frequency of CVD in DM and 
CKD, even in very early stages. On the other hand, our recent research revealed a significant 
impact of minimal heart dysfunction on further development of renal impairment[3]. Then, 
it seems that CVD, CKD and DM shares many risk factors and influences each other in 
various stages. This could be demonstrated as a pyramid with facets of presentations and a 
common pathophysiologic base. Considering this network of associations, we have 
introduced the concept of circulatory (MARC) syndrome, which facilitates understanding, 
evaluation, detection and interventions on the CVD risk factors earlier, easier and more 
effective. This concept preserves the positive features of the so called "metabolic syndrome" 
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but prevents its weaknesses and improves its clinical applications. This leads to a novel 
paradigm in CVD management with new checking points, new targets and better 
achievements in the patients' care. 
2. Epidemiologic trends in CVD risk factors 
CVD has been evolving through 4 epidemiologic transition periods[1] with increasing 
frequency of proportion of death due to CVD during the first 3 stages and a slight decrease 
in the disease rate in the 4th stage, possibly due to controlling CV risk factors. However, it 
seems that a 5th stage is being developed due to epidemic diabetes, hypertension, obesity 
and chronic kidney disease as well as leveling off the smoking session rate in combination to 
social and economic instability in many countries. Consequently, epidemiologic trends in 
CVD and CV risk factors have been changing during the past decades both in developed 
and in developing countries. Developing countries, in particular, experience a substantial 
rise in CVD and younger age at onset of the disease, which is partially attributed to their 
demographic remodeling including a high population growth rate and inverted population 
pyramid with a majority of young individuals [1]. Furthermore, these countries face to a 
"dual epidemiology" of contrasting an undernourished and poor population against a 
significant proportion of overweight and obese groups. The last World Health Organization 
report on global burden of disease and risk factors demonstrated that the highest rates of 
CV death were in Eastern Europe, Central Asia, Middle East and North Africa. Also six out 
of 10 countries with highest rate of diabetes were in Eastern Mediterranean and Middle East 
region. However, there was a considerable heterogeneity in other regions which reflects 
different stages of epidemiologic transitions even in a single country like China[1, 4].  
Eight risk factors (alcohol use, tobacco use, high blood pressure, high body mass index, high 
cholesterol, high blood glucose, low fruit and vegetable intake, and physical inactivity) 
account for 61% of cardiovascular deaths[4]. Moreover, air pollution, climate change, 
psychosocial stressors and maternal-foetal metabolic adaptation are also introduced as 
important CV risk factors[1]. However the pattern of the risk factors differs in subgroups of 
age, gender and patient groups while some factors loses their impact in parallel to 
homogeneity of the factor in the group[5]. It also evolves as a population passes through 
epidemiologic transitions from traditional to emerging risk factors.  
From a practical perspective, primary and secondary prevention must be arranged for 
modifiable risk factors. The Framingham Study and subsequently the INTERHEART study 
have identified the important risk factors and targets for modification. Moreover, an 
analysis of 10 studies across the world in which there has been a decline in CVD mortality, 
demonstrated that risk factor modification was associated with 44% of the decline in the 
Netherlands, 50–54% in the USA, and 76% in North Karelia, Finland. New treatments are 
responsible for 23–47% of the decline in mortality[1]. Although, economic, cultural and 
logistic conditions have various impacts on preventive strategies in different population; risk 
assessment is a fundamental step for any CV preventive strategy.  
2.1 CV risk in diabetes mellitus 
CVD is the leading cause of mortality among DM patients [6, 7] with the prevalence of, 
incidence of, and mortality from all forms of CVD being 2-8 fold higher in diabetics when 
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compared to a non-diabetic population. DM is accompanied with various cardiovascular 
abnormalities including endothelial dysfunction, increased oxidative stress and micro- and 
macrovascular consequences leading to coronary artery disease, left ventricular dysfunction 
(particularly diastolic dysfunction), hypertensive heart disease and reduced cardiac 
reserve[8]. A different trend in CV risk factors has been reported in patients with and 
without DM in Framingham Study from 1970 to 2005. This study demonstrated a greater 
increase in BMI, greater decrease in cholesterol and similar reduction in hypertension in DM 
when compared to non-DM[2].   
The special writing group for the American Heart Association established that the goal of risk 
assessment would be to identify subclinical CVD in patients with DM which would lead to 
better management and improvement in disease morbidity and mortality. Furthermore they 
also designated DM as a “coronary risk equivalent” and indicated that DM patients belong 
in the same risk category as patients with known CVD[9]. This risk increases with age (>35 
yrs), younger age at onset of DM, duration of DM (>10 yrs), presence of microvascular 
complications and other CV risk factors [10, 11]. Screening and CV risk assessment of DM 
patients is also strongly recommended in many guidelines including a French guideline 
which recommended screening for silent myocardial ischemia (including exercise stress 
testing) in DM patients with one additional risk factor [9]. However, the American Heart 
Association recommended exercise testing in this group when individuals plan moderate to 
high intensity exercise[11]. Furthermore, while the hemodynamic response to increased 
physical activity is a predictor of future hypertension [12] and is helpful in the early 
diagnosis of heart failure[13], it might also provide further information about the factors 
contributing to impaired  cardiovascular control even in DM patients without additional 
risk. Accordingly, we demonstrated in a study of more than 17000 patients (including 1722 
DM pts) an impaired hemodynamic response to exercise stress testing in DM group 
compared to non-diabetics and most importantly showed that the responses predicts the 
development of ESRD in diabetic patients[3, 14-16]. (Figure 1) Furthermore, in an outpatient 
setting of patients with diabetes and hypertension; we reported a substantial proportion of 
patients being non-dipper for nocturnal blood pressure. This study also showed an inverse 
relationship between white coat hypertension and arterial stiffness or microalbuminuria[17]. 
A comparison between normal individuals, patients with impaired fasting glucose, and 
diabetic patients did also demonstrate an increment of arterial stiffness in these groups[18]. 
In conclusion, all above evidence indicate subclinical arterial changes early in DM. 
2.2 CV risk in diabetic kidney disease 
About 10-40% of patients with diabetes mellitus (DM) develop nephropathy. Consequently 
with an increasing DM global prevalence and an aging population, DM has become the 
leading single cause of ESRD in many developed and developing countries [19-24]. 
Moreover, it is now proven that even a mild reduction in kidney function is accompanied by 
an increased cardiovascular (CV) risk [25, 26]. In addition, cardiac and renal DM 
complications share many risk factors and markers including microalbuminuria (mA), 
atherosclerosis and arteriosclerosis [27-29]. Therefore, evaluation and treatment of renal risk 
factors should not only prevent progression to End-Stage Renal Disease (ESRD), but also 
reduce CV risk. 
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Fig. 1. Differential response of DM and NDM to the exercise test  in  hypertensive and 
normotensive subgroups 
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While the development and progression of renal damage in DM occurs very slowly, it often 
remains subclinical and undiagnosed for years [30], which inhibits effective prevention and 
intervention at a time when renal damage may be reversible. Therefore, early identification 
of diabetic nephropathy (DN) is a medical priority [31, 32]. Although mA is currently 
regarded as an early marker of DN, it is now preferably considered as a marker of a 
generalized endotheliopathy and then a CV risk marker. However, irreversible damage has 
often occurred when mA is detected [30, 33]. Furthermore, mA may not accurately represent 
the severity of renal damage, absent in marked renal dysfunction [34, 35] or may regress or 
fluctuate during the disease [34, 36]. Consequently, other markers, preferably in their early 
stages, should also be investigated as a potential guide to the progression of ESRD [31].  
Arterial compliance changes occur early in DM and since arterial stiffness is an established 
independent predictor of mortality in the later stages of nephropathy [37-39], it should also 
correlate with renal function and BP profile in the earlier stages of DM.  
Based on the above understanding, we made a large study including several subsets with 
various range of kidney function and compared CV risk factors in DM and non-DM, focusing 
on early stages in particular. The findings indicated that even in early stages of renal 
impairment without clinical presentation, DM patients had a greater level of arterial stiffness 
compared to non-DM. As a result, indices of arterial stiffness could be applied for a better CV 
risk management particularly in DM[40]. (Figure2). Multivariant analysis revealed arterial 
stiffness, hemoglobin, systolic blood pressure and triglyceride as the main determinants of 
renal function in DM (Table 1). Application of artificial neural network for analysis of major 
predictors of kidney function also determined arterial stiffness, hemoglobin, triglyceride, 
diabetes and blood pressure profile among major determinants of renal function. 
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Fig. 2. Difference in the central arterial stiffness (as measured with CF-PWV) between type 
2DM and NDM groups across levels of eGFR 
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Adj.R2 
Model 1
48% 
Model 2
49% 
Model 3
50% 
Model 4
51% 
Model 5
52% 
Model 6
52% 
Model 7 
53% 
Model 8 
52% 
rTr 
0.397 
0.259 
0.403 
0.245 
0.393 
0.249 
0.411 
0.222 
0.410 
0.219 
0.202 
0.116 
0.202 
0.115 
0.298 
0.009 
Male 
Gender 
-0.279 
0.038 
-0.278 
0.036 
-0.263 
0.033 
-0.282 
0.015 
-0.288 
0.012 
-0.275 
0.014 
-0.269 
0.015 
-0.281 
0.012 
CV 
disease 
-0.273 
0.040 
-0.275 
0.037 
-0.269 
0.037 
-0.287 
0.018 
-0.280 
0.020 
-0.283 
0.018 
-0.282 
0.017 
-0.277 
0.021 
Hb 
0.352 
0.010 
0.342 
0.009 
0.329 
0.008 
0.351 
0.002 
0.351 
0.002 
0.356 
0.002 
0.355 
0.001 
0.361 
0.001 
HbA1c 
-0.152 
0.217 
-0.163 
0.161 
-0.153 
0.168 
-0.158 
0.150 
-0.155 
0.154 
-0.149 
0.165 
-0.164 
0.122 
-0.186 
0.082 
TG 
-0.304 
0.014 
-0.294 
0.013 
-0.287 
0.013 
-0.293 
0.010 
-0.288 
0.010 
-0.299 
0.007 
-0.300 
0.006 
-0.273 
0.012 
Peripheral 
DBP 
0.087 
0.597 
0.101 
0.516 
0.129 
0.323 
0.149 
0.225 
0.148 
0.222 
0.158 
0.187 
0.173 
0.142 
 
ACE-I 
0.099 
0.396 
0.105 
0.354 
0.109 
0.328 
0.094 
0.372 
0.089 
0.394 
0.079 
0.440 
  
HR 
-0.199 
0.540 
-0.207 
0.517 
-0.207 
0.513 
-0.207 
0.508 
-0.211 
0.496 
   
ARB 
0.057 
0.597 
0.056 
0.598 
0.065 
0.532 
0.062 
0.541 
    
Age 
-0.075 
0.635 
-0.071 
0.649 
-0.072 
0.642 
     
Peripheral 
SBP 
0.060 
0.689 
0.048 
0.739 
      
Insulin 
-0.040 
0.748 
       
Table 1. Regression models for determinants of eGFR in the DM group, Values are ß (upper 
line) and P value (lower line)  
2.3 CV risk in ESRD  
Cardiovascular disease (CVD) is a common complication in end-stage renal disease (ESRD) 
with a 10 to 30 times greater CVD mortality compared to the general population[41].  
Traditional CV risk factors while more prevalent, cannot fully explain this increased CV 
event rate in ESRD[28] and other factors including increased lipoprotein-a (lipo-a), 
adipokines, asymmetric dimethylarginine (ADMA), hyperhomocysteinemia, 
hyperparathyroidism and arterial stiffness have been implicated [27, 42-46]. In turn, arterial 
stiffness is affected by several hemodynamic and metabolic factors. 
Diabetes mellitus (DM) is the leading cause of ESRD [43]. It is also a major CV risk. Despite 
medications and attempts to control these CV risk factors, CV events still remain the most 
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common cause of mortality both in DM and in ESRD [47-49]. While a greater risk of CV 
events is expected in DM compared to non-DM patients with ESRD , the available reports 
regarding the risk profile in DM and non-DM patients with ESRD are conflicting [42, 43, 50-
53]. Likewise interactions between ESRD and DM in the development and progression of 
arterial stiffness are not completely clear [54, 55]. As a result of several metabolic factors 
which contribute in arterial stiffening, vascular calcification is proposed as the fundamental 
phenomena in arterial stiffness and is certainly a frequent finding in ESRD and DM [56-58]. 
However the mechanisms for the development of vascular calcification are not completely 
understood. In particular, reports of its relationship with calcium homeostatic mechanisms 
including parathyroid hormone (PTH), phosphate and the calcium-phosphate product 
(Ca×P) and vitamin D are inconsistent[58-62].  
In an attempt to clarify classic and emerging risk factors in ESRD, we conducted a study of 
100 diabetic and non-diabetic (paired matched for age and gender) individuals with ESRD 
and demonstrated blood pressure, heart rate, height and renal function as well as metabolic 
profiles, including cholesterol, homocystein, lipo(a) and CRP were comparable. However, 
carotid-femoral PWV (12.3 ±0.5 vs 10.3± 0.2; P<0.001) and pulse pressure (71.2± 2.2 vs 64.2 
±2.4) were significantly greater in the DM group, despite a comparable AIx and waveform 
reflection time. Multivariate analysis demonstrated PTH to be a significant PWV 
determinant after adjustment for DM, renal function and BP (P=0.038). As a particular novel 
finding, calcium-phosphate product had a u-shape association with central and peripheral 
PWV (P<0.05), that is both low and high levels of calcium-phosphate product increases the 
CV risk in this group which was similar to its relationship with mortality, reported by Block 
et al. In conclusion, arterial stiffness as an established, independent and strong predictor of 
mortality in ESRD patients [63, 64] is possibly the factor that links cardiac and renal disease 
(Figure 3)[25]. Consequently, we proposed a model that can explain association of the 
factors (Figure 4 ). 
2.4 CV risk in kidney transplanted patients 
Kidney transplant patients have a lower risk of CVD compared to dialysis patients, even 
after controlling important source of selection bias including age[65]. However, CVD is still 
a common cause of post-transplant death [19]. Nevertheless, classic risk factors cannot fully 
explain the CV risk in this population. It is reported that the Framingham CV risk score 
significantly underestimates the risk of ischemic heart disease in transplant patients [66] and 
therefore, non-classic risk factors including C-reactive protein, homocystein and renal 
function as well as arterial stiffness may contribute in CV risk in this population [67, 68].  
In support to the previously demonstrated findings our group studied 100 kidney 
transplanted patients (including 33 DM) and reported with a comparable classic CV risk 
factors, homocystein and renal function had a greater arterial stiffness when compared to 
non-DM. Also an improvement in central arterial stiffness was observed after a year of 
follow-up[69, 70]. This is in line with the other evidence that cardiac function in DM 
transplant candidates is carefully evaluated prior to transplantation and LV systolic, 
diastolic function and arterial compliance improves shortly after a successful renal 
transplant [71-75]. It was also concluded that assessment of arterial stiffness may improve 
pre-transplantation risk assessment both in donors and recipients[70]. 
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Fig. 3. Non-linear relationship between central (left) and peripheral (right) pulse wave 
velocity with calcium-phosphorus product in ESRD 
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Fig. 4. Hypothetical model for explaining Renal-Cardiac Cross talk 
3. Fundamentals in CVD risk assessment  
The global epidemic of diabetes and chronic kidney diseases and their effect on the 
increased incidence of CVD, stresses on undeniable requirement for a timely effective CVD 
risk assessment in order to implement prevention strategies. 
Risk assessment is a fundamental component of primary and secondary preventive 
strategies and an important skill in clinical epidemiology in particular for chronic diseases 
such as diabetes mellitus (DM) with potentially preventable multi-organ involvement. 
Although many risk factors have been identified as promoting DM complications, the 
presence of a risk factor only demonstrates the “risk” or the “possibility” of the given 
outcome since not all patients with the factor develop an adverse outcome and vice versa. 
However from a preventive point of view the medical approach is the attempted reduction 
of all risks factors so as to decrease this possibility. Nevertheless, decision thresholds are 
important determinants of risk factor management. 
Traditionally, patients are assessed and managed based on the presence or absence of 
individual risk factors with a target point for each risk factor being determined and medical 
interventions (commonly by separate specialties) applied to achieve these targets. However, 
these risk factors also interact and can augment or diminish each others effect. In other 
words, patients with a particular risk factor might be more prone or more susceptible to be 
influenced by another risk factor. Moreover risk factors may have a synergistic effect thereby 
producing a greater impact beyond a summation of their individual risk. Accordingly, 
different target points have been assigned for various patient subgroups. For instance, 
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recent practice guidelines suggested different target blood pressures for DM patients with 
and without proteinuria [76, 77]. Nevertheless, most risk factors such as BP have a linear 
relationship with the adverse outcome (i.e. CV events or mortality), even when levels are 
below the arbitrarily defined cut-off points[78, 79]. In an attempt to overcome this problem, 
new definitions such as pre-hypertension, pre-DM and pre-microalbuminuria have been 
added to recent practice guidelines [76, 77, 80], although they may have enhanced 
uncertainty and confusion rather than improve patient care. 
While the target point approach appears to be straightforward, there may be a substantial 
risk of unnecessary treatment or neglect when treating certain patients. Consequently, a 
multifactorial risk assessment approach whereby a planned therapy is based on an individual’s 
absolute risk is now encouraged [81]. This multidisciplinary approach is expected to be 
more effective, both medically and economically. 
The simplest way to estimate a multifactorial global risk is to use the number of the present 
risk factors. For instance the number of present components of the metabolic syndrome 
associated with the risk of CV disease in DM or the development of renal impairment [82, 
83]. Alternatively, each factor can be graded in an individual patient and scored (e.g. using 
the GCS in comatose diabetic patients) and then the total score is considered as 
representative of the severity of the condition and predictive for the outcome [84]. A more 
scientific approach would be to sort the factors according to their importance or the strength 
of their association and calculate a total risk or a "risk score" by summation of the weighted 
utilities of the factors. The appointed weight could be based on expert opinion or better still 
on more objective criteria. This technique should simulate the medical decision making 
process by a medical practitioner where the better the weighting the more accurate the 
diagnosis. Statistical methods including inferential analysis, discriminating analysis and 
probabilistic methods should facilitate this process. While multivariate analyses, including 
linear and logistic regression, are commonly used for this purpose, factor selection and 
modeling is the back bone of risk score development. Inappropriate modeling substantially 
damages the risk score performance [85]. Moreover, while the developed risk score can be 
ideally used in a similar population, it should not be extrapolated to other populations or 
even in the same population after a few years due to life style and risk factors changes, 
available medications or advanced diagnostic methods for the given outcome. Therefore, 
they must be repeatedly validated in the target population and re-evaluated to remain 
applicable in clinical practice. This process would yield an equation that would predict the 
outcome [86]. Although linear models are relatively simple and powerful methods for 
prediction, their essential assumptions including normality, independence and uniformity 
of variance must be fulfilled to be applicable [87]. Therefore, non-linear transformation is 
occasionally required and regression techniques can then be used to find the best 
discriminant function or decision boundary. However in most clinical situations many 
factors have equivocal discriminatory power and risk factors have interactions and clusters 
overlap. As a result the data space is multidimentional [86]. In these cases, intelligent 
systems including artificial neural networks can improve modeling and prediction. They 
provide a framework by selecting the most important discriminant items and appropriate 
form of boundaries [86, 88, 89]. Many [85] but not all [90, 91] studies have reported that 
neural networks outperform conventional statistical methods. There are a few experiments 
of ANN application in clinical practice, including our innovative system for chronic kidney 
insufficiency that is already mentioned in this chapter. 
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4. Clustering CV risk factors: A critical appraisal 
In medical science, a "syndrome" is defined as an “aggregate of symptoms and signs or 
several conditions associated with any morbid process and constituted together they 
produce the picture of the disease”[92]. These components are usually caused by a unifying 
underlying pathology and their combination confers a risk that is different from the sum of 
the parts. The main purpose of such a description is to help in the diagnosis, treatment and 
prognosis of the disease.  
The Metabolic Syndrome has been a useful construct in clinical practice as well as a valuable 
model to understand the interactions of diverse CV risk factors. However the concept has 
been critically appraised for its limited validity and clinical usefulness. This necessitates a 
novel model for a better and more effective risk assessment in clinical practice. 
The metabolic syndrome was first described by G.M. Reaven in 1988 to describe a cluster of 
risk factors contributing to the incidence of diabetes mellitus (DM), cardiovascular (CV) 
events and also mortality[93]. The definition of this syndrome remains a matter of debate 
and has been revised on several occasions by different organisations[94-99]. Despite some 
diversity, obesity, hyperglycemia, dyslipidemia and hypertension have been constant 
syndrome components and the central concept of such descriptions is the unity of the 
background pathophysiologic process and the interaction between the elements. Several 
epidemiologic studies have illustrated the relationship between the metabolic syndrome, CV 
events and mortality[100-107]; however the syndrome was recently criticised by the 
American Diabetes Association for its modest consistency and limited clinical 
application[102] and the use of the term metabolic syndrome was discouraged. 
Furthermore, its clinical use has recently been described as artificial, confusing and 
ambiguous recast of traditional risk factors [108-111], with no advantage [110] and even 
more false positive rate in predicting diabetes and CV disease [112] compared to the usual 
Framingham risk assessment. In contrast, INTERHEART, a large worldwide prospective 
study demonstrated that the impact of risk factor clustering is much more than simply 
multiplying the risk of individual factors for acute myocardial infarction[113]. Although the 
general clinical strategy against the presence of each risk factor (either single or in 
combination with others) remains constant, the threshold of interventions may differ by 
accepting or denying the metabolic syndrome[114]. Hence, while the current definitions are 
controversial, evidence-based syndrome improvement must target better clinical 
applicability and higher predictive power of the modifiable outcomes.  
Insulin resistance is presumed to be the common pathway for all features of the metabolic 
syndrome[115]; yet insulin related measurements are not standardized and vary widely 
[116, 117]. Furthermore, despite the widespread assumption among clinicians, 
hyperinsulinemia and insulin resistance are not equivalent terms[102]. Besides, while 78% of 
individuals with metabolic syndrome have insulin resistance, only 48% of patients with 
insulin resistance manifest the metabolic syndrome[118]. Consequently, Leptin resistance 
has been suggested as an alternative mechanism which also leads to hyperinsulinemia and 
other metabolic syndrome features [119].Therefore the association of hyperinsulinemia and 
other elements of this syndrome are not constant and many other factors may also play 
important roles as underlying mechanisms in clustering the risk factors. In other words, the 
metabolic syndrome is beyond insulin resistance, the phenomena which may simply be one 
of many abnormalities linked to a more fundamental, truly unifying pathophysiology [102, 
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120]. Likewise, the metabolic syndrome diagnosis is not always associated with a higher CV 
risk, for example an increased risk was not observed in elderly diabetic and non-diabetic 
American Indians as well as women with suspected CV disease but normal 
angiography[121-123]. In addition the application of different syndrome definitions can 
cause a 15-20% disagreement in patient classification [102] thereby changing the predictive 
value of the syndrome diagnosis for CV disease and mortality [101, 106, 124]. This 
accumulating evidence demonstrates that the association of the current syndrome 
components with CV disease and with each other is uncertain. Even reports supporting the 
metabolic syndrome state that “detecting the metabolic syndrome is only one part of the 
overall CV risk assessment and is not an adequate tool to estimate the 10-year risk for 
coronary heart disease”[125]. This is probably due to the many other related factors not 
included as syndrome criteria. In fact, residual analysis of many longitudinal studies 
demonstrates a high unexplained variance (as much as 47%) when metabolic syndrome 
components were considered as independent variables[102]. By and large, the current body 
of evidence strongly suggests that the metabolic syndrome definition needs to be 
standardized and additional factors included[114]. For example, despite several 
epidemiologic studies demonstrating the relationship between the metabolic syndrome and 
microalbuminuria, this factor was only incorporated into the World Health Organisation 
syndrome criteria in 1998 [126] which was not expressed in any other descriptions. Likewise 
renal failure, now accepted as an independent CV risk factor, as well as anaemia, have not 
been considered as a part of the metabolic syndrome. Moreover, the impact of 
endothelioarterial pathology has been overlooked and cardiac disease has been considered 
simply as an outcome and not an interacting part of the syndrome.  
We  have introduced the term of “circulatory syndrome” as a more refined clinical construct 
which is composed of many disease markers including Metabolic, Arterial, Renal and  
cardiac components (simply abbreviated as: “MARC”)  
5. Circulatory (MARC) syndrome 
Circulatory syndrome is a cluster of risk markers with synergic effects. The proposed 
syndrome consists of eight major components (Figure 5), as follows (in the “MARC” order):  
 Abnormal glucose metabolism 
 Dyslipidemia 
 Hypertension  
 Arterial stiffness  
 Microalbuminuria 
 Renal impairment 
 Anaemia 
 Left ventricular dysfunction 
All of these “markers” occur on a background of oxidative stress, inflammation, 
hypercoagulability and endotheliopathy (underlying factors) and can be accelerated by 
factors such as aging, obesity, smoking and physical inactivity (predisposing factors). 
Furthermore they can be simply and non-invasively assessed in outpatient clinical settings. 
While the mechanisms underlying the circulatory syndrome are poorly understood, it must 
be strongly stated that vascular-endothelial pathways link all and are of pathological 
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significance. Activation of the renin-angiotensin system, insulin resistance and increased 
sympathetic activation are all by-products of the underlying pathogenic process. Since these 
markers represent the extent of the underlying disease process, they could also manifest as 
risk factors for other components and thereby enhance their development. Considering the 
interrelationships, the final outcome in this model can be considered to be CV events, stroke 
or renal failure; all of which are associated with general circulatory health. Consequently the 
condition of the circulatory system and these markers is directly related to the mortality 
rate. 
Primordial studies demonstrate a robust and valid utility of the "MARC" syndrome concept 
and a useful risk assessment approach in chronic kidney disease and diabetes mellitus. 
However, larger prospective cohorts are required for further validation of the concept.  
 
Fig. 5. An illustrative Circulatory Syndrome; A cluster of cardiac, renal, arterial and 
circulatory markers of disease that are interconnected through the endothelium; the 
common media (underlying factors) include oxidative stress, inflammation, 
hypercoagulability state and endotheliopathy which contribute in the main mechanisms of 
the phenomena; the third dimension (precipitating factors) include age, obesity, physical 
inactivity and smoking which accelerate the phenomena. 
Rationale For Inclusion Of The Components 
The Circulatory Syndrome shares some elements with the metabolic syndrome. However it 
includes additional metabolic and non-metabolic factors (Table2).  
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Abnormal Glucose Metabolism 
          Fasting Plasma Glucose >6.1 mmol/l ; or 
          2hr post prandial >7.8 mmol/l 
Hypertension 
          SBP≥130 mmHg; and/or 
          DBP≥ 85 mmHg 
GFR 
          MDRD eGFR <90 ml/min/1.73 m2 
Microalbuminuria 
         Urinary  Albumin creatinine ratio (ACR) [two occasions] 
          >2.5 (male) 
          >3.5 (female) 
Arterial Stiffness 
          Upper quartile for PWV, AI or ambulatory PP in the population 
Left ventricular dysfunction 
          Any evidence of systolic or diastolic; 
          Imaging techniques or  
          Exercise test  (MET <6, impaired systolic BP response) or  
          BNP> 100 pg/ml 
          Previous myocardial infarction 
Anemia 
          Hb< 12 female 
          HB<13 male 
Dyslipidemia 
          Triglyceride ≥ 1.7 mmol/l or 
          HDL<1 (male) or <1.3 (female) mmol/l or 
          Elevated Apolipoprotein B 
GFR: Glomerular Filtration Rate, PWV: Pulse Wave Velocity, AI: Augmentation Index, PP: Pulse 
Pressure, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure, MET: Estimated multiples of 
resting oxygen uptake, BNP: Brain Natriuretic Peptide, HDL: High Density Lipoprotein 
Table 2. Preliminary Diagnostic Criteria for Circulatory Syndrome;  
(1) Abnormal glucose metabolism: Diabetes and abnormalities in glucose metabolism are 
well known risk factors for cardiac, arterial and renal disease as well as anemia [127, 128]. 
Although insulin resistance and hyperinsulinemia can be attributed to these complications, 
they may occur with or without insulin resistance because several other mechanisms 
including advanced glycation end products, autonomic nervous instability, imbalance 
between the renin-angiotensin system and nitric oxide, hemodynamic changes and 
endothelial dysfunction with subsequent ADMA accumulation (an inhibitor for nitric oxide 
synthesis) and adiponectin deficiency also contribute in the process [120, 129, 130]. 
Furthermore, albuminuria, arterial stiffness and intima media thickness increase with the 
increasing number of metabolic syndrome components even before fulfilling the diagnostic 
criteria for the syndrome, particularly amongst subjects with type 2 DM [131]. In addition, 
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alterations in BP circadian rhythm and BP profile including non-dipper nocturnal BP is now 
considered as a manifestation of arterial remodelling and is associated with other 
manifestation of endothelial dysfunction including mA and arterial stiffness. 
(2) Lipid abnormalities: Dyslipidemia including increased LDL and TG as well as low HDL 
is a major risk in patients with chronic renal disease, hypertension and diabetes[105, 132-
134]. Genetic variants of lipoprotein lipase correlate with the presence and degree of 
albuminuria [135]. Dyslipidemia is an independent determinant of progression toward 
chronic kidney disease and is a known cardiac risk factor [28, 44]. It also contributes to 
arterial micro-inflammation and atherosclerosis[136]. From different perspective, the 
correction of lipid abnormalities can reduce albuminuria in subjects with the metabolic 
syndrome [137], decrease inflammatory markers[138], improve renal function[139], increase 
arterial compliance[140], improve left ventricular function [138] and prevent CV events[136]. 
It is noteworthy that obesity was not incorporated into our criteria since there is an opposite 
relationship between BMI and survival in CKD (reverse epidemiology) [108] and therefore 
less obese patients with CKD reach to ESRD. 
(3) Blood pressure abnormalities: Hypertension is introduced as the leading risk factor of 
death according to WHO report of global health [4].Hypertension and altered blood 
pressure circadian rhythm are common co-morbidities with diabetes and pre-diabetic states 
as well as kidney disease[141].  BP is strongly associated with arterial stiffness and promotes 
left ventricular dysfunction[29] . In the setting of insulin resistance the vasodilatory effect of 
insulin can be lost but its renal sodium reabsorption stimulation is preserved. In addition, 
insulin-induced sympathetic activity increases the prevalence of hypertension in the 
metabolic syndrome [120]. Furthermore, while salt sensitivity is associated with impaired 
glucose metabolism, oxidative stress, dyslipidemia and insulin resistance [142, 143] ,it also 
increases efferent glomerular arteriolar tone and thereby raises glomerular capillary 
pressure and proteinuria [144] as well as inducing blood pressure abnormalities via renal 
sodium reabsorption and sympathetic overactivity[145].  
(4) Arterial stiffness: Decreased arterial compliance is influenced by both atherosclerosis 
and arteriosclerosis, as well as functional arterial abnormalities [29, 146]. It occurs very early 
in the process of kidney disease and DM [147, 148], even preceding microalbuminuria [149] 
and has also been observed in normal individuals with a close family history of DM [148]. 
Recent studies have illustrated that increased central arterial stiffness in 
hypercholesterolemia, even in newly diagnosed individuals, is associated with low-grade 
systemic inflammation [150, 151]. Arterial stiffness in turn increases LV load and leads to 
ventricular stiffness and diastolic dysfunction [152, 153]. It has also been suggested as the 
linking factor between renal impairment and CV diseases [25]. Of great importance, 
decreased arterial compliance predicts mortality in variant patient groups, independently 
from other risk factors [38, 154-156]. 
(5) Microalbuminuria is now accepted as a marker of renal, cardiac and arterial damage 
being predictive for the further development of CV events, renal failure and DM [25, 134].  It 
is also closely associated with the prevalence of anaemia [128] , hypertension [157] and 
metabolic syndrome components [131]. Microalbuminuria commonly occurs early in 
subjects with abnormal glucose metabolism [147, 158] and is correlated with dyslipidemia 
[159], arterial stiffness[160, 161] and increased coagulability[162] as well as inflammatory 
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markers[163, 164]. Furthermore the presence of microalbuminuria predicts ventricular 
dysfunction, coronary heart disease and exercise intolerance[165, 166].  
(6) Renal impairment: Kidney function can not be isolated from the health of the heart and 
arteries and is also associated with the metabolic syndrome components. Alterations in 
glomerular structure are seen very early in the obesity-mediated metabolic syndrome[82] . 
Renal hemodynamic reserve is already impaired in patients with asymptomatic left 
ventricular dysfunction [167]. In addition, the kidney has an important role in insulin and 
glucose metabolism [168]and insulin resistance has a predictive value for chronic kidney 
disease [82, 95]. Renal function has been called the Cinderella shoe of CV risk profile [169] 
and the impact of even minor renal dysfunction on CV function is now well established [25] 
with endothelial cell dysfunction is likely to be the linking factor between renal and cardiac 
disease[25, 134, 170]. However endothelial dysfunction in turn is a consequence of 
inflammation and oxidative stress and is accelerated by these phenomena[171] and is also 
correlated with a number of the metabolic syndrome components [131]. Decreased arterial 
compliance increases ventricular wall tension and stiffness and consequently diastolic 
dysfunction[153]. This in turn may lead to partial renal ischemia, followed by activation of 
the renin-angiotensin system and tubulointerstitial damage[170]. On the other hand, 
hyperfiltration which is observed in the early stages of diabetic nephropathy and 
hypertension [172, 173], leads to increased glomerular pressure and resultant sclerosis which 
in turn accelerates hypertension[141].  
(7) Anemia: Anemia is a common finding in DM and has multifactorial mechanisms[128]. 
Early tubulointerstitial occurs which disease decreases EPO production and moreover 
inflammatory cytokines reduce EPO responsiveness leading to anaemia[174]. It is also 
associated with the level of albuminuria[128] .Anaemia in turn, increases the progression 
toward CKD, oxidative stress, tissue ischemia, ventricular stress and mortality[175-177]. Of 
interest, a recent study demonstrated the contribution of anemia to the frequent diastolic 
dysfunction in DM, as well as its association with brain natriuretic peptide (BNP) and 
suggested using this factor to identify diabetic patients at increased risk of cardiac 
dysfunction [175]. Therefore, accumulating evidence has introduced anemia as an important 
risk factor for the circulatory system. On the other hand, correction of anemia improves the 
prognosis in chronic kidney disease, heart failure and DM and its complications as well as 
decreasing mortality [177-179] 
(8) Left Ventricular dysfunction: In contrast to the metabolic syndrome, ventricular 
function is proposed as an interactive part of the circulatory syndrome. This idea is 
supported by reports of a lack of a relationship between the metabolic syndrome and 
mortality in individuals who have good cardiorespiratory fitness [180]. On the other hand 
even a mild stage of ventricular failure, as manifested by impaired exercise response is 
predictive for mortality[181, 182].Ventricular function determines blood pressure and renal 
perfusion and in turn is influenced by kidney function, anemia and arterial stiffness and 
microalbuminuria [153, 183]. Diastolic dysfunction occurs early in DM, is correlated with 
arterial stiffness and affects exercise response [184]. Furthermore, it has been reported that 
asymptomatic patients with type 2 DM have subclinical ventricular dysfunction which is 
related to glycated hemoglubin and LDL cholesterol [185]. Also a recent in vitro study 
demonstrated that myocyte relaxation and Ca2+ handling are abnormal in early uremia, 
leading to uremic cardiomyopathy [186]. 
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Additional evidence: It is of great interest that some hypoglycaemic agents reduce blood 
pressure via suppression of the renin-angiotensin system and some ACE inhibitors can 
reduce insulin resistance in addition to reducing microalbuminuria and arterial stiffness, 
which raises the possibility of the presence of a common pathway for the adverse effects of 
hyperglycemia and hypertension[187-189].  Likewise, some lipid lowering agents may 
exhibit mild anticoagulant and hypotensive effects [190] and angiotensin inhibitors have 
anti-inflammatory actions [191] which also indicate a possible common source of these 
abnormalities.  
It could be expected that genetic predisposition including nephron underdosing, ACE gene 
polymorphism, congenital tubular defects and also some other factors such as aging, obesity 
and smoking produce organ damage susceptibility [133, 192-194].   
The above evidence suggests that a genetic profile or a common pathologic process induces 
a network of metabolic (including alterations in glucose, salt, insulin and lipid metabolism) 
and hemodynamic abnormalities ( due to renin-angiotensin system stimulation, sympathetic 
overactivity and decreased nitric oxide bioavailability) which are followed by anaemia, 
hypercoagulability, tissue ischemia, arterial stiffness, hypertension, renal and cardiac 
dysfunction, the other features of the circulatory syndrome (figure 5). 
Underlying Pathology 
It is proposed that inflammation is the fuel that “burns” the circulatory syndrome. The 
association between inflammatory markers and both DM and hypertension is so strong that 
these diseases has recently been redefined as inflammatory diseases, as has atheroma[195-
198]. Advanced glycation end products (AGEs) which accumulate in DM activate 
inflammatory cells[195]. Likewise, insulin resistance has a strong link with inflammation, 
although additional mechanisms including genetic factors may influence this 
relationship[199]. In addition, high LDL cholesterol induces oxidative stress and increases 
inflammation[200]. On the other hand HDL and  apolipoprotein A1 have anti-inflammatory 
and anti-oxidant properties[201]. Hence, metabolic elements of the syndrome are correlated 
with inflammation. 
Inflammation is known to be a modifier of the relationship between microalbuminuria and 
hypertension [163, 202]. Hence, CRP has been frequently promoted as a part of the metabolic 
syndrome [102, 125, 203]. Moreover, inflammatory markers such as CRP are now considered 
to be independent predictors of DM [195] and its complications including left ventricular 
hypertrophy, endothelial dysfunction, albuminuria and renal failure [25, 171, 204, 205]. 
There is a close relationship between inflammation and hypercoagulability [164, 206]. 
Furthermore, hypercoagulability is also linked to the metabolic syndrome, dyslipidemia, 
anaemia and even the hemodynamic response to exercise [201, 207-209]. It is also associated 
with a poorer outcome in coronary artery disease, heart failure and is correlated with the 
severity of target-organ damage including renal impairment [210-212]. Consequently, 
diabetic and metabolic syndrome patients are at high risk for thrombotic events [213-215] 
and have an increased level of clotting factors including tissue plasminogen activator (tPA) 
and von Willenbrand Factor (vWF) and D-dimer when compared to the controls[216]. 
Additionally, insulin and lipids may have direct inhibitory effects on coagulation and 
platelet function through nitric oxide, a pathway that is impaired in DM patients [217]. 
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By and large, this interlinking mesh of inflammatory mediators, oxidative stress, 
endotheliopathy and hypercoagulability makes a common soil for development of the 
circulatory (MARC) syndrome. 
6. New targets and novel approache to CVD risk modification 
The above description of the “circulatory syndrome” clearly has clinical applications. The 
identification of commonly evaluated markers such as blood pressure, glucose and lipids in 
a patient should also prompt a search for other markers which make up the circulatory 
syndrome. A suspected circulatory syndrome should facilitate decision making for 
diagnostic procedures in asymptomatic but high risk patients.  Also treatment of each 
syndrome component should be accompanied by management of the other components. 
Furthermore, any difficulty in treating one circulatory syndrome marker should probably 
leads to a more aggressive treatment program for other components as is currently 
proposed in patients with renal disease, diabetes and associated hypertension. Hence, 
management of the proposed "Circulatory Syndrome" would need an interdisciplinary 
approach with the collaboration of different medical subspecialties. 
7. A novel approach to diabetic nephropathy (DN) 
The evidence of the close relationship of DM, hypertension, renal function, cardiac function, 
arterial compliance and metabolic factors have already been discussed. Accordingly the 
proposed concept of the “Circulatory Syndrome” could be applied as a novel approach to DN. 
This approach should overcome the potential barriers to achieving target points in DM and 
enhance medications efficacy. According to this new perspective, the treatment of co-
morbidities in DM including heart failure, renal failure, arterial stiffness, anemia and the 
hypercoagulability state as well as reducing any potential inflammation source (e.g. chronic 
infections, immunology-mediated disease and sensitivities) should enhance adherence to 
the target points and disease control. This needs a "multidisciplinary approach" to CV risk 
management in DM, in which a clinical epidemiologist or a care plan manager must have a 
central role. Additionally a global risk score is preferred to the current target points for each 
risk factor so that the threshold of intervention is clearly defined based on several potential 
risk factors and assessment of adherence to the guideline is estimated by risk score 
alterations. 
8. New markers 
Given the serious limitations of using mA as a single disease marker in screening [31], a 
multifactorial approach is required to boost screening efficacy and allow reliable risk 
estimation in DN. The Japanese Society of Nephrology is the only professional organization 
that has formally added renal hypertrophy and urinary type IV collagen to their guideline 
as early markers of the existence of DN [218]. There is also evidence for other potential 
markers including glomerular, tubular, interstitial, endothelioarterial, genetic and cellular 
markers. However their applicability, validity and reliability must be investigated in a 
parallel test with mA.  
These markers help risk stratification for patients without mA or with fluctuating 
proteinuria. Furthermore, they facilitate diagnosis of other facets of diabetic kidney damage 
and also explain the link between cardiac and renal complications of DM. 
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9. New strategies 
The threshold of action for screening, intervention and assessment must be revised based on 
current DN knowledge and should be followed by altered strategies to define high risk 
patients. It should also include all pathological aspects of DN including those proposed in 
the “Circulatory Syndrome”, although these will need to be refined, particularly in 
asymptomatic patients.   
In terms of treatment, research findings about renal benefits of the renin-angiotensin-
aldosterone system (RAAS) blocking irrespective of blood pressure and albuminuria [219] 
have not fully integrated into Clinical practice guidelines. Likewise, while recent research 
has demonstrated advantages of lipid lowering agents even in patients with normal lipid 
levels [220], the threshold for action remains at higher levels. Similarly, treating anemia has 
a significant impact on renal function preservation even in early stages of renal disease and 
erythropoietin therapy has potential advantages for cardiac, neural, endothelial and renal 
protection [221] as well as a general benefits due to reduction in the oxidative stress, insulin 
resistance and cytokine accumulation in DM patients (as mentioned in our recently 
published paper [222]); yet decision criteria are not completely clear in this regard. With 
accumulating evidence, the threshold for anemia correction is expected to be reduced in a 
near future. 
Regarding follow-up, recent reliable and practical assessments should be considered 
including central and/or ambulatory BP. Also for renal function, eGFR (based on the MDRD 
or the Cockcroft-Gault formula) is superior to plasma creatinine [223].  
10. New treatment targets  
It might be argued that with considering the circulatory syndrome concept and increasing 
number of the action sites, the number of medication is ought to be increased. Then since 
increased number of medications usually leads to reduced patients’ compliance, such an 
approach may not only fail to improve disease control, but also make the problem more 
complex. While possibly true, there are potential solutions. For instance many experts 
encourage “poly-pills” which include a combination of the required agents. Although it may 
have better patients’ acceptance, it cannot reduce the potential adverse effect of 
polypharmacy. Alternatively and ideally, the type of treatment must be revised in order to 
meet multiple targets using a single medication (“super-pills”).  
New treatment options: The marked advantages of using ACE-I and ARB has been 
appreciated with a 60-70% risk reduction the risk of progression to overt nephropathy in 
several large clinical trials [224-226]. However this optimistic result would not be completely 
achieved in routine practice and they can not abrogate the progression of kidney disease. 
This may suggest incomplete blockage of the RAAS by current medication dose which allow 
“aldosterone synthesis escape”[227].  Although a recent meta-analysis of randomized trials 
with ACE-Is and ARBs yielded only a small renoprotection benefit (and no benefit in DM) 
and demonstrated a smaller benefit in large studies [228], it contradicts previous meta-
analysis [229, 230] and seems to be biased by the accessory results from the 
Antihypertensive and Lipid Lowering treatment to prevent Heart attack Trial (ALLHAT) 
which was not originally designed for renal outcome evaluation [231].  
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A combination with beta blockers or calcium channel blockers or a diuretic was previously 
recommended in the practice guidelines, newer combinations of ACE-I and indapamide, 
ACE-I and spirinolactone and a double blockage of RAAS (ACE-I and ARB) have been 
demonstrated promising in terms of lowering BP and mA, which is also supported by the 
new understanding of ACE-2 enzyme, angiotensin recptor-2 and the role of aldosterone in 
CKD progression [232] In addition, using pioglitazone or rosiglitazone in combination with 
sulphonylurea with or without metformine has also been suggested by experts as an 
effective combination; however the available clinical data is still limited. Finally, it is 
noteworthy that while identification and management of hypertensive patients with 
elevated heart rate (with beta-blockers or calcium antagonists)is recommended by expert 
consensus [233], non-selective beta blockers (e.g. propranolol) generally decrease GFR by 
lowering cardiac output. In contrast, the ß1-selective agents (e.g. metoprolol and atenolol) 
may have a beneficial effect on declining GFR as well as protecting heart against heart 
failure. However these may also have adverse effect on plasma glucose and atenolol must be 
adjusted in renal failure due to its impaired renal clearance. On the other hand non-selective 
vasodilating beta blockers (Carvedilol and Labetalol) not only reduce BP but also have 
antioxidant and renoprotective effects [234]. Finally, considering of erythropoietine (EPO) in 
medical management of diabetes is expected to improve CV health in DM [222, 235]. 
New agents: Several animal models have suggested many potential candidates for prevention 
and treatment of DN. Renoprotective effect of ALT-711 (a cross link breaker of the advance 
glycosylation end product), ruboxistaurin (an inhibitor for protein kinase C), eplerenone (a 
new aldosterone antagonist), thiamine and a modified heparin glycosaminoglycan have 
been reported, as being effective in reducing albuminuria and renal lesions [232, 236, 237]. 
However, very few human studies have been conducted in human of which the 
combination of ACE-I and omepatrilat (an endopeptidase inhibitor), sulodexide (a 
glycosaminoglycan), Pirfenidone (TGF-ß inhibitor) and pimagedine (a second generation 
inhibitor of advanced glycation end product) have had dramatic beneficial effects in DM 
patients [232, 236, 238]. There are also some evidence of the efficacy of folic acid on 
endothelial function improvement in different groups of patients including type 2 DM [239]. 
Developing novel drugs opposing the action of TGF-ß, connective tissue growth factors, 
cytokines and reactive oxygen species is the next step. Also by recognizing the role of 
relaxin [240], urotensin II [241] and vascular calcification contributors, additional medication 
might one day be available. 
Multipotential agents: Accumulating evidence demonstrates the polydimentional action of 
some medications on glycaemic and BP control, reducing lipid and mA and improvement in 
arterial compliance. For instance, blocking of the renin-angiotensin system has anti-diabetic 
and anti-inflammatory effects as well as antihypertensive actions and improves mA and 
arterial stiffness at the same time [187, 189, 191]. This also applies to some lipid lowering 
agents [190, 220]. Likewise, insulin-sensitizing thiazolidinediones (TZDs) ameliorate mA 
and are antihypertensive [242]. Also metformin improves both endothelial function and the 
metabolic syndrome [243]. From a different point of view, treating anemia with 
erythropoietin may also have cardiac, renal, neurohormonal and metabolic benefits due to 
anemia correction of anemia and the cytoprotective effects of erythropoietin perse [221, 222, 
244]. Several researches are being conducted to introduce and develop novel EPO 
replacement therapies such as synthetic erythropoietic proteins, continuous EPO receptor 
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activators (CERA), EPO gene transfer using retroviral vectors and implementation of EPO 
producing cells in A-V fistula graft which will create a revolution in related therapies [222]. 
With the axial role of RAAS in the pathogenesis of DN, non-hemodynamic effects of ACE-I 
and ARB including their action on TGF-ß, extracellular matrix and cytokines have the focus 
of several studies in recent years [237]. According to a recent study Losartan improves 
resistance artery lesions and prevents TGF-ß production in untreated hypertensive patients 
[245]. In addition, ACE-I agents potentiate bradykinin-induced tissue plasminogen activator 
(t-PA) release leading to endothelial fibrinolytic function [246, 247]. Consequently several 
studies have indicated that the renoprotective of these drugs is independent of their 
antihypertensive effect [229].  
The recognition of a new class of nuclear receptors named “peroxisome proliferators-
activated receptor” (PPAR) has provided an additional field for action against DN and 
consequently its CV complications. Rosiglitazone is a PPAR-γ agonist which was 
demonstrated as being effective in lowering blood pressure and reversing insulin resistance 
[248]. Likewise, several studies have verified the multipotential action of PPAR-α agonists 
including Fenofibrate in reducing fasting blood glucose, ameliorating insulin resistance, 
decreasing mA, correction of lipid metabolism, suppressing collagen by mesangeal cells, 
preventing glomerulosclerosis as well as antihypertensive [242, 249]. This body of evidence 
supports the potential impact of multipotential drugs in the future treatment of DN. 
11. Conclusion 
Early diagnosis and management of CV risk, particularly in diabetes and chronic kidney 
disease requires a new insight and subsequently a novel approach to the disease is 
mandatory. While our studies demonstrated various facets of the interactions between renal, 
cardiac, arterial and metabolic factors, the proposed “Circulatory Syndrome” can facilitate 
formulation of new strategies for the better diagnosis and management of CV risk. 
Accordingly, a multidisciplinary evaluation of glycemic control, lipids, anemia, blood 
pressure profile, albuminuria, GFR and ventricular function as well as an assessment of 
arterial compliance (as an axial element) provides adequate information for early and 
effective identification of high risk patients for progression toward CVD. The proposed 
concept of the “Circulatory (MARC) Syndrome” is expected to facilitate this revolution by a 
multidisciplinary approach. 
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